Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Efficacy of QLS12010 in Healthy Volunteers and Atopic Dermatitis
NCT06946641Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of QLS12010 in atopic dermatitis (AD) (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Treatment emergent Adverse Events at 1 month. Started Mar 2025; status: recruiting.
02
Drugs
QLS12010
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06946641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946641.